Paul Rothman serves as Executive at CANCER GENETICS, INC, where they oversee executive responsibilities. Since joining the company, Paul Rothman has executed 3 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Feb 10, 2026 involved receiving (via award) 733 shares valued at $0.
Paul Rothman currently holds 1,670 shares of CANCER GENETICS, INC (CGIX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Paul Rothman has been a net neutral trader of CGIX stock. They have purchased $0 and sold $0 worth of shares.
Paul Rothman's most recent insider trade was on Feb 10, 2026, when they sold 733 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| May 22, 2014 | CGIX | $0 | Award | 5,000 | $N/A | Discretionary |